FDA OKs Varisolve varicose vein therapy trial:
This article was originally published in Clinica
Executive Summary
BTG's subsidiary Provensis has gained approval from the US FDA to begin a pilot clinical study of its noninvasive procedure for treating varicose veins. The technique, called Varisolve, involves injecting a microfoam version of a standard sclerosing liquid into the vein under ultrasound guidance. Efficacy data from an ongoing trial in Europe are expected to become available by the end of the year, at which time BTG plans to begin discussions with potential sales and marketing partners. London, UK-based BTG forecasts 2006 and 2005 launch dates for Varisolve in the US and in Europe, respectively.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.